Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Metabolic & Endocrine/Insulin Resistance

Metabolic & Endocrine

Insulin Resistance

49

Pipeline Programs↗

23

Active Trials↗

21

Companies Involved↗

Insulin resistance is a moderately active landscape with 49 programs across 21 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

27/100

Mech. Concentration

7/100

Completion Rate

81/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Nanjing Chia-tai Tianqing Pharmaceutical

1 program

Pipeline

Programs by Phase

Preclinical35

Estradiol

Novo Nordisk

Nicorandil

Merck & Co.

Somatropin

Eli Lilly

Heparin

Baxter Healthcare Corporation

Rifaximin

Salix

Phase 110

Olanzapine

MODAG GmbH

[1-13c] Sodium Acetate

Columbia University

[6,6-2h2] D-Glucose

Columbia University

Growth Hormone

Pfizer

Alpelisib

Novartis

Phase 23

Metreleptin

Chiesi Farmaceutici S.p.A.

Hypoglycemic Drug

Cairo University

TLC-3595 Dose 1

OrsoBio, Inc

Phase 31

D-Chiro-Inositol Combined With Metformin

Campus Bio-Medico University

Approved

No programs

Analysis

Trial Status

188

clinical trials

Completed118 · 63%

Unknown status20 · 11%

Terminated13 · 7%

Withdrawn13 · 7%

Recruiting11 · 6%

Active, not recruiting7 · 4%

Other6 · 3%

Clinical Trials

Trial Activity

188 trials

Neuromuscular Electrical Stimulation: A Novel Treatment for Improving Metabolism

Recruiting·University of Texas, El Paso·Preclinical·NCT06722391·80 enrolled

Alpelisib Challenge Test (ACT) for Assessment of Pancreatic β-Cell Reserve, Pilot & Feasibility Study

Recruiting·CColumbia University·Phase 1·NCT07778524·15 enrolled

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Recruiting·CColumbia University·Phase 1·NCT06354088·32 enrolled

Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations With Insulin Resistance

Recruiting·AAdventHealth Translational Research Institute·N/A·NCT07516509·36 enrolled

A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults

Recruiting·MMayo Clinic·N/A·NCT06820658·80 enrolled

The Muscle Phenotype and Cardiometabolic Health Monitoring Project

Recruiting·UUniversity Ghent·N/A·NCT07678736·250 enrolled

Reversal of Lipid-Induced Insulin Resistance

Recruiting·YYale University·Preclinical·NCT02193295·250 enrolled

Investigating the Insulin Resistance in Individuals With Type 2 Diabetes

Recruiting·—·N/A·NCT06428968·30 enrolled

Acupuncture or Metformin for Insulin Resistance in Women With PCOS

Recruiting·KKarolinska Institutet·Phase 2·NCT02647827·303 enrolled

Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause

Recruiting·—·Phase 1/2·NCT06806345·40 enrolled

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Recruiting·UUniversity of Kansas Medical Center·Phase 1/2·NCT04715022·23 enrolled

Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents: a Pilot Trial

Active, not recruiting·UUniversity Hospital, Basel, Switzerland·Preclinical·NCT04966299·30 enrolled

Effects of Antipsychotics on Brain Insulin Action in Females: A Randomised Placebo-Controlled, Crossover Multi-Modal Neuroimaging Study

Active, not recruiting·CCentre for Addiction and Mental Health·Preclinical·NCT06251635·15 enrolled

Fructose: Substrate, Stimulus, or Both?

Active, not recruiting·Touro University, California·Preclinical·NCT04168372·35 enrolled

Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM

Active, not recruiting·—·Phase 4·NCT06860841·16 enrolled

Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)